The proven champion vs the triple-threat newcomer. One receptor vs three , and the Phase 3 gap is wider than anyone expected.
Bottom line: TRIUMPH-1 closed the debate on efficacy: retatrutide delivered 25.0% mean weight loss at 80 weeks on 12mg, with 30.3% loss at 104 weeks in the BMI≥35 subgroup , and 45.3% of participants hit ≥30% loss. That is bariatric surgery territory. Semaglutide's best result is 14.9% in STEP 1. The gap isn't close. The triple GLP-1/GIP/glucagon mechanism adds something semaglutide's single-agonist approach cannot: direct stimulation of fat oxidation and energy expenditure via the glucagon receptor. Semaglutide still holds real advantages , FDA approval, seven years of post-market safety data, proven cardiovascular outcomes (SELECT trial: 20% MACE reduction), and prescribability today. Retatrutide has no approval yet (FDA submission expected 2026, approval timeline 2027 at earliest), and access is limited to unregulated research peptide suppliers. The verdict: if maximum fat loss is the only goal and you accept trial-era evidence, retatrutide is the stronger compound. If you need something your doctor will prescribe, insurance will cover, or that has a cardiovascular outcomes trial behind it, semaglutide is the rational choice today.
| Semaglutide | Retatrutide | |
|---|---|---|
| Category | GLP-1 receptor agonist | Triple GLP-1/GIP/glucagon receptor agonist |
| Mechanism | Activates GLP-1 receptors: suppresses appetite, slows gastric emptying, improves insulin secretion. One signal pathway. | Simultaneously activates GLP-1 (appetite/insulin), GIP (insulin sensitivity, fat storage modulation), and glucagon (direct fat oxidation, energy expenditure, liver fat clearance). Three synergistic pathways. |
| Standard dose range | 0.25mg → 2.4mg weekly (injection); 3mg → 14mg daily (oral Rybelsus) | 1mg → 12mg weekly (injection). Phase 3 used 4mg, 9mg, and 12mg arms. |
| Injection frequency | Once weekly (injection) or once daily (oral) | Once weekly (injection only) |
| Weight loss , trial results | 14.9% at 68 weeks (STEP 1, 2.4mg). 9.6% at 68 weeks in T2D (STEP 2). | Phase 2: 24.2% at 48 weeks (12mg). Phase 3 TRIUMPH-1: 25.0% at 80 weeks (12mg); 30.3% at 104 weeks in BMI≥35 subgroup. |
| Patients reaching ≥20% weight loss | ~33% in STEP 1 (2.4mg arm) | Phase 2: ~67% at 12mg. Phase 3 full responder analysis pending , 45.3% of patients reached ≥30% in the 104-week extension. |
| Top side effects | Nausea (~37–44%), constipation (24%), diarrhea (30%), vomiting (24%). GI events peak at each dose escalation step. | TRIUMPH-1 at 12mg: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3%. GI burden is higher than sema at top doses. Increased resting heart rate also reported. |
| Evidence tier | Tier 1 , multiple Phase 3 trials complete, FDA-approved since 2017–2021, dedicated cardiovascular CVOT (SELECT) | Tier 2 , Phase 2 published (NEJM 2023), Phase 3 TRIUMPH-1 positive topline (May 2026). FDA submission expected 2026; approval timeline 2027. |
| FDA approval status | Approved. Ozempic (T2D, 2017), Wegovy (obesity, 2021), Rybelsus (oral T2D, 2019). | Not approved. Regulatory submission anticipated 2026; GlobalData projects 2027 approval. No approved branded product in any country. |
| Compounding and availability (2026) | FDA shortage resolved 2025. 503B bulk compounding largely ended. 503A patient-specific compounding still exists in limited cases. Availability tighter than 2024. | No approved product. Research-grade peptide from unregulated suppliers only. No insurance path. No prescription route in any country. |
| Cardiovascular outcomes data | SELECT trial: 20% MACE reduction in obese patients with established CVD (n=17,604). Uniquely strong evidence base for obesity drug. | TRIUMPH-3 (CVD population) ongoing. No cardiovascular outcomes data published yet. |
| Approximate monthly cost | Branded Wegovy ~$1,349/mo. Compounded (where legally available) ~$150–300/mo. | Research peptides: ~$240–500/mo (unregulated). Future branded price estimated $1,000–1,500/mo post-approval. |
tierA: Tier 1
tierB: Tier 2
summary: Semaglutide has full FDA approval, a massive Phase 3 trial base across STEP 1–8, and the SELECT cardiovascular outcomes trial. Retatrutide now has Phase 3 TRIUMPH-1 positive topline data (May 2026) plus Phase 2 published in NEJM, but remains unapproved. The Phase 3 weight loss numbers confirm and exceed Phase 2 , this is no longer a 'promising' compound, it is a validated one without a regulatory home yet.
trials: [{"name":"STEP 1 (semaglutide)","pmid":"33567185","result":"14.9% mean body weight loss vs 2.4% placebo at 68 weeks (n=1,961)","citation":"Wilding JPH et al. N Engl J Med. 2021"},{"name":"STEP 2 (semaglutide in T2D)","pmid":"33667417","result":"9.6% weight loss at 68 weeks in patients with type 2 diabetes (n=1,210)","citation":"Davies M et al. Lancet. 2021"},{"name":"SELECT (semaglutide cardiovascular outcomes)","pmid":"37952131","result":"20% reduction in MACE in patients with obesity + established CVD, no diabetes (n=17,604)","citation":"Lincoff AM et al. N Engl J Med. 2023"},{"name":"Retatrutide Phase 2 , Jastreboff (NEJM)","pmid":"37366315","result":"24.2% mean weight loss at 48 weeks (12mg); 17.5% at 24 weeks. ~50% of 12mg participants achieved ≥25% weight loss (n=338)","citation":"Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526"},{"name":"TRIUMPH-1 (retatrutide Phase 3, topline)","pmid":null,"result":"25.0% mean weight loss at 80 weeks (12mg arm); 17.6% at 4mg; 23.7% at 9mg; 3.9% placebo (n=2,339). BMI≥35 extension to 104 weeks: 30.3% mean loss; 45.3% achieved ≥30% weight loss","citation":"Eli Lilly topline data, May 2026. Full peer-reviewed publication pending."},{"name":"TRIUMPH-4 (retatrutide Phase 3, knee osteoarthritis)","pmid":null,"result":"28.7% mean body weight loss at 68 weeks (average 32.3 kg / 71.2 lbs); also demonstrated significant knee pain reduction in obese adults with osteoarthritis","citation":"Eli Lilly topline data, December 2025."}]
{"applies":false,"name":"You switch, not stack","intro":"Semaglutide and retatrutide are not used together. They share the GLP-1 receptor , combining them would stack side effects without adding meaningful benefit. You choose one.","phases":[],"note":"The real question is sequencing. Many people start on semaglutide because it's available and approved today, then plan to transition to retatrutide once it reaches approval (estimated 2027). Others who can access research peptides go directly to retatrutide. There is no established clinical protocol for transitioning between them , start retatrutide from the lowest dose regardless of previous semaglutide dose to manage GI tolerance during the switch."}
Based on Phase 3 data: retatrutide 12mg produced 25.0% mean weight loss at 80 weeks in TRIUMPH-1. Semaglutide 2.4mg produced 14.9% at 68 weeks in STEP 1. That is a 10 percentage point gap. At 104 weeks in the high-BMI extension, retatrutide hit 30.3%. No semaglutide trial comes close to those numbers. This is not a marginal or uncertain difference , it's nearly double the weight loss.
Phase 3 TRIUMPH-1 topline results were released May 2026 and are positive. The full peer-reviewed safety analysis is pending publication. The Phase 2 NEJM paper (Jastreboff 2023, PMID 37366315) showed a manageable GI side effect profile. Key unknowns: long-term cardiovascular outcomes (no CVOT yet) and the glucagon receptor's heart rate effects at population scale. The drug will not be approved until regulators review the complete dataset , which is the appropriate quality gate. Research peptide access skips that gate.
Several real reasons. Semaglutide is FDA-approved and prescribable today; retatrutide is not. Semaglutide has the SELECT cardiovascular outcomes trial , a 17,604-person study proving it cuts MACE by 20% in obese patients with established CVD. Retatrutide has no cardiovascular outcomes data. Semaglutide has seven years of post-market safety data. There is an oral pill form (Rybelsus). Insurance coverage, doctor familiarity, and supply reliability all favor sema. Retatrutide is the stronger fat-loss tool. Semaglutide is the safer, more accessible, better-evidenced medical intervention. Different priorities, different answer.
GLP-1 and GIP primarily work through appetite suppression and insulin regulation , they reduce how much you eat and improve insulin sensitivity. The glucagon receptor does something different: it directly stimulates hepatic fatty acid oxidation (the liver burning fat for fuel), increases resting energy expenditure, and promotes adipose tissue lipolysis. The theory is that this shifts weight loss composition toward fat over lean mass and drives additional caloric burn even at rest. It's also why retatrutide is interesting for liver fat (NAFLD/MASLD) beyond what semaglutide achieves through weight loss alone. Phase 3 body composition data will tell us how much of this mechanistic theory shows up in practice.
No. Both activate the GLP-1 receptor. Combining them stacks GI side effects without additive fat loss benefit. You pick one. Sequencing , starting sema now and switching to reta on approval , is a logical strategy. Using both simultaneously is not.
Not through any approved or regulated channel. Research peptide suppliers sell it, but retatrutide has no FDA or EMA approval as of September 2026. Quality, purity, and dosing accuracy from unregulated suppliers are not guaranteed. Eli Lilly is expected to file for approval in 2026, with a projected 2027 approval. If you want retatrutide through a legitimate channel, you are waiting.
Semaglutide is FDA-approved for T2D (Ozempic) and showed 9.6% weight loss plus meaningful A1C reductions in the STEP 2 diabetic patient trial. Retatrutide's TRIUMPH-2 trial (T2D population) is underway but hasn't reported. For T2D management today, semaglutide is the evidence-backed, approved, prescribable choice. Retatrutide's potential for T2D is real , triple agonism should be potent for insulin resistance , but the data does not exist yet for that population.
It comes back. STEP 1 extension data showed participants regained about two-thirds of lost weight within one year of stopping semaglutide. No long-term discontinuation data exists for retatrutide yet, but the mechanism is the same class , weight loss is maintained by the drug, not locked in permanently. These are long-term or indefinite interventions, not 6-month courses with a finish line.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
